Vertex Pharmaceuticals (VRTX) Enterprise Value (2009 - 2026)

Vertex Pharmaceuticals' Enterprise Value history runs 18 years deep, the most recent figure standing at -$7.2 billion for Q1 2026.

• In Q1 2026, Enterprise Value fell 16.86% year-over-year to -$7.2 billion; the TTM figure through Mar 2026 stood at -$7.2 billion (down 16.86% YoY), while the FY2025 annual figure was -$6.6 billion, down 8.05% from the prior year.
• Enterprise Value for Q1 2026 stood at -$7.2 billion, down from -$6.6 billion in the prior quarter.
• The five-year high for Enterprise Value was -$5.8 billion in Q2 2024, with the low at -$11.9 billion in Q3 2023.
• The 5-year median for Enterprise Value is -$8.2 billion (2022), against an average of -$8.5 billion.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value tumbled 43.24% in 2022, then jumped 48.42% in 2024.
• Vertex Pharmaceuticals' Enterprise Value stood at -$10.8 billion in 2022, then declined by 4.08% to -$11.2 billion in 2023, then surged by 45.48% to -$6.1 billion in 2024, then fell by 8.05% to -$6.6 billion in 2025, then slipped by 9.66% to -$7.2 billion in 2026.
• Business Quant data shows VRTX's Enterprise Value at -$7.2 billion in Q1 2026, -$6.6 billion in Q4 2025, and -$6.3 billion in Q3 2025.